
More than 10 percent of patients treated with aspirin therapy for primary cardiovascular disease prevention were likely inappropriately prescribed medication, according to a new study in the Journal of the American College of Cardiology that examined practice variations in aspirin therapy.

According to a new report by iData Research, ultrasound equipment providers in the United States are likely to see stable, reliable growth in the coming years. Already a billion-dollar industry in the U.S., the ultrasound imaging equipment market is projected to pass the $2 billion mark by 2020.
University Hospitals (UH) Case Medical is now offering a new, non-invasive test for coronary artery disease designed to help physicians develop the right treatment plan for each patient. Developed by HeartFlow Inc., computed tomography-fractional flow reserve (CT-FFR) is a non-invasive imaging technology specifically designed to offer insight on both the extent of the blockage, as well as whether it is impacting blood flow to the heart. UH Case Medical Center’s Daniel Simon, M.D., will be first to use the CT-FFR test in the United States.
SPONSORED CONTENT — Studycast is a comprehensive imaging workflow system that allows healthcare professionals to work ...
Our daily diet may help lower bad cholesterol, in turn reducing risk for heart disease, according to health researchers in the Jan. 7 edition of the Journal of the American Heart Association. Avocados are known to be a nutrient-dense food, high in monounsaturated fatty acids. Previous studies have suggested that avocados are a cholesterol-lowering food, but this is the first study — to the researchers' knowledge — to look at health implications of avocados beyond monounsaturated fatty acids.
Ambry Genetics announces the launch of cardiovascular genetic testing panels for inherited cardiomyopathies and arrhythmias. These feature an intuitive, tiered approach to testing for hypertrophic cardiomyopathy, long QT syndrome and Brugada syndrome.
Daiichi Sankyo Co. Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Savaysa (edoxaban) tablets, an oral, once-daily selective factor Xa-inhibitor, to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF).
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
Lithoplasty is a balloon-based technology that utilizes integrated lithotripsy to disrupt both superficial and deep calcium and normalize vessel wall compliance prior to low-pressure balloon dilatation.
ECRI Institute’s 2015 Top 10 Hospital C-Suite Watch List, available as a free public service, answers key questions on new and emerging health technologies that potentially provide new ways to treat patients, improve care and reduce costs.
CardioFocus Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation (AF), announced that it has executed an exclusive, multi-year distribution agreement with Japan Lifeline Co. Ltd.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
Transcatheter Technologies GmbH has announced that it is expanding its product family to include Tresillo, a transcatheter mitral valve implantation (TMVI) version.
Medtronic, Inc. announced the initiation of a randomized clinical trial in Europe to assess the benefits of ablation using the Medtronic Artic Front Advance cryoballoon as a first-line treatment for atrial fibrillation (AF) patients.
W. L. Gore & Associates Inc. announced that the Gore Viabahn Endoprosthesis has received CE Mark approval to improve blood flow in symptomatic obstruction of peripheral veins, excluding the venae cavae and pulmonary veins.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
CardioKinetix Inc. announced results of a pooled analysis study of the catheter-based Parachute ventricular partitioning device. Twelve-month clinical data from PARACHUTE III, a study of 100 post-market European patients with ischemic heart failure treated consecutively between 2011 and 2013, were presented at the 2014 TCT Conference in Washington, D.C., and the 2014 HFSA Conference in Las Vegas.
The Healthcare Colloquium announced that CHI Franciscan Health is the first Accredited Heart Failure System in the Northwest.
With today’s aging population in the United States, we are experiencing an increased occurrence of cardiovascular disease including heart failure, degenerative valve disease and atrial fibrillation. These clinical challenges, along with changes in healthcare economics and standards, require efficient, effective and streamlined diagnostic solutions. These solutions must deliver critical added benefits including: